Showing results (11-20 of 518) with videos related to
Sort By:
Pageof 52
Cancer Treatment Reviews|October 23, 2024
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectivesClaudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.JTO Clinical and Research Reports|January 23, 2023
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European SurveyMarco Tagliamento, Jordi Remon, Matteo Giaj Levra, et al.Lung Cancer (Amsterdam, Netherlands)|May 31, 2016
Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC networkJordi Remon, Nicolas Girard, Julien Mazieres, et al.Plos One|August 23, 2017
Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancerCécile Jovelet, Jordan Madic, Jordi Remon, et al.Cancer Treatment Reviews|July 4, 2024
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancerArianna Marinello, Marco Tagliamento, Arianna Pagliaro, et al.European Journal of Cancer (Oxford, England : 1990)|January 2, 2023
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysisJordi Remon, Guillermo Villacampa, Francesco Facchinetti, et al.The Journal of Liquid Biopsy|March 3, 2025
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applicationsClaudia Parisi, Marco Tagliamento, Laila Belcaid, et al.Future Oncology (London, England)|January 29, 2015
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitorsNoemi Reguart, Jordi RemonTranslational Lung Cancer Research|March 26, 2015
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patientsMargarita Majem, Jordi RemonTranslational Lung Cancer Research|March 26, 2015
EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistanceJordi Remon, Margarita MajemPageof 52